Long‐term sustainability of glycaemic achievements with second‐line antidiabetic therapies in patients with type 2 diabetes: A real‐world study
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.1111/dom.13288
Abstract: To inform patients and their carers about both the probability of reducing glycated haemoglobin (HbA1c) to clinically desirable levels and the sustainability of such control over 2 years with major second‐line antidiabetic therapies, in individual… read more here.
Keywords: line antidiabetic; line; long term; antidiabetic therapies ... See more keywords
FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13669
Abstract: The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of… read more here.
Keywords: antidiabetic therapies; fda guidance; cardiovascular risk;